Retrospective assessment of the utility of an iron-based agent for contrast-enhanced magnetic resonance venography in patients with endstage renal diseases.
about
Current and potential imaging applications of ferumoxytol for magnetic resonance imaging.Four-dimensional, multiphase, steady-state imaging with contrast enhancement (MUSIC) in the heart: a feasibility study in children.Accelerated ferumoxytol-enhanced 4D multiphase, steady-state imaging with contrast enhancement (MUSIC) cardiovascular MRI: validation in pediatric congenital heart disease.4D MUSIC CMR: value-based imaging of neonates and infants with congenital heart diseaseFerumoxytol as an off-label contrast agent in body 3T MR angiography: a pilot study in children.Safety and technique of ferumoxytol administration for MRI.Blood pool contrast agents for venous magnetic resonance imaging.Emerging applications for ferumoxytol as a contrast agent in MRI.Contrast-enhanced pulmonary MRA for the primary diagnosis of pulmonary embolism: current state of the art and future directions.Feasibility of ferumoxytol-enhanced neonatal and young infant cardiac MRI without general anesthesia.Use of blood pool agents with steady-state MRI to assess the vascular system.Ferumoxytol vs. Gadolinium agents for contrast-enhanced MRI: Thoughts on evolving indications, risks, and benefits.Ferumoxytol enhanced black-blood cardiovascular magnetic resonance imaging.Ferumoxytol-enhanced magnetic resonance angiography for the assessment of potential kidney transplant recipients.Crossover comparison of ferumoxytol and gadobenate dimeglumine for abdominal MR-angiography at 3.0 tesla: Effects of contrast bolus length and flip angle.
P2860
Q30234702-3D1F2617-5A68-4307-974D-51EC7AE4CAA9Q30367692-11E7281D-4665-47AD-9A48-6A647F5E61BDQ30395371-DCFF9E23-F984-4CA6-BD69-FF4BCB9822E2Q30400570-BB801C12-CDBF-421B-A7B0-6065859283BAQ35656127-D0586438-4D33-4D03-BA17-663B0438915EQ36862859-035E27CA-BE23-4174-BD8E-F43845AB13AFQ37570773-99793009-3DDE-44F8-9F6F-57779212D4D8Q38224182-E6DF8A3C-A16B-4DA4-9982-19050D6C14CDQ38743614-6255DC44-A294-4558-B93E-1DA72A874733Q38966351-3274D544-F161-48BF-9407-6A578E70D774Q39250421-8A697963-DE7B-4843-A967-DABBE6D035AAQ46071655-310B8D41-51F8-43D8-8AC1-627403F5A494Q47137741-EE1B2F25-9A39-4B47-A8DD-7675038F265CQ47199588-EE9CA2CF-7D6F-4B2B-8E6F-EB2F9FB44538Q48215270-AF13AC28-FD69-4849-A4B7-C224068838D5
P2860
Retrospective assessment of the utility of an iron-based agent for contrast-enhanced magnetic resonance venography in patients with endstage renal diseases.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Retrospective assessment of th ...... with endstage renal diseases.
@en
Retrospective assessment of th ...... with endstage renal diseases.
@nl
type
label
Retrospective assessment of th ...... with endstage renal diseases.
@en
Retrospective assessment of th ...... with endstage renal diseases.
@nl
prefLabel
Retrospective assessment of th ...... with endstage renal diseases.
@en
Retrospective assessment of th ...... with endstage renal diseases.
@nl
P2093
P2860
P356
P1476
Retrospective assessment of th ...... s with endstage renal diseases
@en
P2093
Amy Neville
Charles Y Kim
Danielle Seaman
Mustafa R Bashir
Rekha Mody
Tracy A Jaffe
P2860
P304
P356
10.1002/JMRI.24330
P577
2013-10-15T00:00:00Z